Teriparatide
Osteoporosis in selected high-risk patients
Evidence: Strong FDA-reviewed clinical evidence
Administration: Daily injection
Score 8.6/10Read Review →Evidence and regulatory context for peptide-based treatments connected to hormonal / endocrine.
Abaloparatide
Osteoporosis in selected high-risk patients
Evidence: Strong FDA-reviewed clinical evidence
Administration: Daily injection
Score 8.3/10Read Review →CJC-1295
Investigational hormonal and body-composition research
Evidence: Limited clinical data
Administration: No approved route
Read Review →Ipamorelin
Investigational hormonal and body-composition research
Evidence: Limited human trials
Administration: No approved route
Read Review →Established / approved options
Teriparatide and abaloparatide have product-specific endocrine and bone indications.
Being researched
CJC-1295 and ipamorelin are unapproved and not recommended for hormone optimization.
How to use this page
Established options appear before experimental compounds. Goal relevance never overrides regulatory status or evidence quality.
Next step
Open the relevant treatment review for sources, risks, contraindications, and evidence gaps.
MyPeptideQuest
Information only. Not medical advice. No dosing or self-treatment instructions are provided.